Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environment
V. Maltez, C. Arora, R. Sor, Q. Lian, R. H. Vonderheide, R. N. Germain, K. T. Byrne
This study shows that agonistic anti-CD40 converts Tregs into Type 1 effectors in the tumor microenvironment via IL-12 and IFN-γ signaling from dendritic cells.
bioRxiv · Oct 17, 2022 · PreprintImmunology